Primary sources below were reviewed for this research. Their publication or update dates differ from this document’s review date. Manufacturer pages establish published programme descriptions and terms, not independently verified service performance.
- FDA — GLP-1 compounding policy clarification, including the April 1, 2026 update. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- FDA — Proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulks list, April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- FDA — FD&C Act provisions applying to human drug compounding. https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
- California State Board of Pharmacy — Verify a licence. https://www.pharmacy.ca.gov/about/verify_lic
- California State Board of Pharmacy — Nonresident sterile compounding pharmacy application. https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
- FDA — Registered outsourcing facilities. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- FDA — Form 483 frequently asked questions. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- FDA — Exemptions under the Drug Supply Chain Security Act. https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- FDA — Dosing errors associated with compounded injectable semaglutide. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- FDA — Concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Eli Lilly — LillyDirect patient FAQs. https://www.lilly.com/lillydirect/faq
- Novo Nordisk — NovoCare delivery programme terms and conditions. https://www.novocare.com/eligibility/delivery.html
- HHS — Business associates guidance and FAQs. https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
- FDA — What telehealth companies should know when promoting compounded drugs. https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- fda.gov · Source 2 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
- pharmacy.ca.gov · Source 4 ↗https://www.pharmacy.ca.gov/about/verify_lic
- pharmacy.ca.gov · Source 5 ↗https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
- fda.gov · Source 6 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 7 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- fda.gov · Source 8 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- fda.gov · Source 9 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- fda.gov · Source 10 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- lilly.com · Source 11 ↗https://www.lilly.com/lillydirect/faq
- novocare.com · Source 12 ↗https://www.novocare.com/eligibility/delivery.html
- hhs.gov · Source 13 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
- fda.gov · Source 14 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs